Chemotherapeutic targeting of myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizadeh, Darya, Katsanis, Emmanuel, Larmonier, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960296/
https://www.ncbi.nlm.nih.gov/pubmed/24653963
http://dx.doi.org/10.4161/onci.27359
_version_ 1782308155079786496
author Alizadeh, Darya
Katsanis, Emmanuel
Larmonier, Nicolas
author_facet Alizadeh, Darya
Katsanis, Emmanuel
Larmonier, Nicolas
author_sort Alizadeh, Darya
collection PubMed
description Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.
format Online
Article
Text
id pubmed-3960296
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39602962014-03-20 Chemotherapeutic targeting of myeloid-derived suppressor cells Alizadeh, Darya Katsanis, Emmanuel Larmonier, Nicolas Oncoimmunology Author's View Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes. Landes Bioscience 2014-01-01 /pmc/articles/PMC3960296/ /pubmed/24653963 http://dx.doi.org/10.4161/onci.27359 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Alizadeh, Darya
Katsanis, Emmanuel
Larmonier, Nicolas
Chemotherapeutic targeting of myeloid-derived suppressor cells
title Chemotherapeutic targeting of myeloid-derived suppressor cells
title_full Chemotherapeutic targeting of myeloid-derived suppressor cells
title_fullStr Chemotherapeutic targeting of myeloid-derived suppressor cells
title_full_unstemmed Chemotherapeutic targeting of myeloid-derived suppressor cells
title_short Chemotherapeutic targeting of myeloid-derived suppressor cells
title_sort chemotherapeutic targeting of myeloid-derived suppressor cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960296/
https://www.ncbi.nlm.nih.gov/pubmed/24653963
http://dx.doi.org/10.4161/onci.27359
work_keys_str_mv AT alizadehdarya chemotherapeutictargetingofmyeloidderivedsuppressorcells
AT katsanisemmanuel chemotherapeutictargetingofmyeloidderivedsuppressorcells
AT larmoniernicolas chemotherapeutictargetingofmyeloidderivedsuppressorcells

Ejemplares similares